PHREESIA INC (PHR) Stock Fundamental Analysis
USA - NYSE:PHR - US71944F1066 - Common Stock
23.25 USD
-0.16 (-0.68%)
23.25 USD
0 (0%)
Taking everything into account, PHR scores 4 out of 10 in our fundamental rating. PHR was compared to 35 industry peers in the Health Care Technology industry. While PHR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PHR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PHR had negative earnings in the past year.
PHR had a positive operating cash flow in the past year.
In the past 5 years PHR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.
1.2 Ratios
PHR has a Return On Assets of -5.89%. This is in the better half of the industry: PHR outperforms 68.57% of its industry peers.
Looking at the Return On Equity, with a value of -8.07%, PHR is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHR has a better Gross Margin (68.02%) than 65.71% of its industry peers.
In the last couple of years the Gross Margin of PHR has remained more or less at the same level.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PHR has been increased compared to 5 years ago.
PHR has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.08 indicates that PHR is not in any danger for bankruptcy at the moment.
The Altman-Z score of PHR (6.08) is better than 82.86% of its industry peers.
PHR has a debt to FCF ratio of 0.42. This is a very positive value and a sign of high solvency as it would only need 0.42 years to pay back of all of its debts.
The Debt to FCF ratio of PHR (0.42) is better than 80.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that PHR is not too dependend on debt financing.
The Debt to Equity ratio of PHR (0.02) is better than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.42 | ||
| Altman-Z | 6.08 |
ROIC/WACCN/A
WACC9.71%
2.3 Liquidity
PHR has a Current Ratio of 2.12. This indicates that PHR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHR (2.12) is comparable to the rest of the industry.
PHR has a Quick Ratio of 2.12. This indicates that PHR is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.12, PHR perfoms like the industry average, outperforming 45.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
PHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
PHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.31%.
Measured over the past years, PHR shows a very strong growth in Revenue. The Revenue has been growing by 27.46% on average per year.
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.23%
Revenue 1Y (TTM)15.31%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.83%
3.2 Future
PHR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
PHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.66% yearly.
EPS Next Y95.04%
EPS Next 2Y52.11%
EPS Next 3Y53.29%
EPS Next 5YN/A
Revenue Next Year14.05%
Revenue Next 2Y13.08%
Revenue Next 3Y12.72%
Revenue Next 5Y11.66%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
PHR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
PHR is valuated quite expensively with a Price/Forward Earnings ratio of 72.69.
PHR's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of PHR to the average of the S&P500 Index (23.30), we can say PHR is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 72.69 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as PHR.
PHR's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.94 | ||
| EV/EBITDA | 675.51 |
4.3 Compensation for Growth
PHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHR's earnings are expected to grow with 53.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.11%
EPS Next 3Y53.29%
5. Dividend
5.1 Amount
PHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.25
-0.16 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners99.81%
Inst Owner Change0%
Ins Owners4.56%
Ins Owner Change-2.57%
Market Cap1.39B
Analysts85
Price Target34.83 (49.81%)
Short Float %5.92%
Short Ratio3.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)78.63%
Min EPS beat(2)41.66%
Max EPS beat(2)115.6%
EPS beat(4)4
Avg EPS beat(4)51.25%
Min EPS beat(4)8.94%
Max EPS beat(4)115.6%
EPS beat(8)8
Avg EPS beat(8)37.38%
EPS beat(12)12
Avg EPS beat(12)31.19%
EPS beat(16)15
Avg EPS beat(16)26.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.27%
Min Revenue beat(2)-0.37%
Max Revenue beat(2)-0.18%
Revenue beat(4)0
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)-0.18%
Revenue beat(8)2
Avg Revenue beat(8)-0.13%
Revenue beat(12)5
Avg Revenue beat(12)0.4%
Revenue beat(16)9
Avg Revenue beat(16)1.43%
PT rev (1m)5.06%
PT rev (3m)7.99%
EPS NQ rev (1m)94.19%
EPS NQ rev (3m)94.58%
EPS NY rev (1m)65.72%
EPS NY rev (3m)65.72%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 72.69 | ||
| P/S | 3.1 | ||
| P/FCF | 49.94 | ||
| P/OCF | 26.93 | ||
| P/B | 4.67 | ||
| P/tB | 9.82 | ||
| EV/EBITDA | 675.51 |
EPS(TTM)-0.42
EYN/A
EPS(NY)0.32
Fwd EY1.38%
FCF(TTM)0.47
FCFY2%
OCF(TTM)0.86
OCFY3.71%
SpS7.51
BVpS4.97
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | 6.2% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score7
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.42 | ||
| Debt/EBITDA | 2.35 | ||
| Cap/Depr | 84.53% | ||
| Cap/Sales | 5.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 2655.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 6.08 |
F-Score7
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.23%
EPS Next Y95.04%
EPS Next 2Y52.11%
EPS Next 3Y53.29%
EPS Next 5YN/A
Revenue 1Y (TTM)15.31%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.83%
Revenue Next Year14.05%
Revenue Next 2Y13.08%
Revenue Next 3Y12.72%
Revenue Next 5Y11.66%
EBIT growth 1Y73.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year249.5%
EBIT Next 3Y64.62%
EBIT Next 5Y37.25%
FCF growth 1Y132.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.75%
OCF growth 3YN/A
OCF growth 5Y108.09%